Syngene’s collaboration with Zoetis started in 2011
Syngene International announced the signing of a 10-year agreement with a leading animal health company, Zoetis, to manufacture the drug substance for Librela (bedinvetmab), a first-in-class monoclonal antibody used for treating osteoarthritis in dogs.
Syngene’s collaboration with Zoetis started in 2011. Over the past 11 years, Syngene has undertaken development work on several monoclonal antibodies for use in animal health, including developing and manufacturing clinical supplies of treatment for allergic or atopic dermatitis, now widely used, and Librela.
This agreement, initially centred on Librela, paves the way for the development and manufacturing of other molecules in the coming years and is expected to be worth up to $500 million to Syngene over 10 years, subject to regulatory approvals and market demand.
Jonathan Hunt, MD and CEO, Syngene International, said, “We are delighted to be expanding our partnership with Zoetis. This multi-year agreement marks an inflection point for our Development and Manufacturing Services Division and we look forward to completing the regulatory inspections that will be required. This 10-year agreement will position Syngene as a leading Contract Development and Manufacturing Organisation (CDMO) in animal health globally.”
Nick Ashton, Executive Vice President and President, Global Manufacturing and Supply, Zoetis, said “At Zoetis, we are committed to delivering high-quality innovative solutions to our customers through our global supply network. By advancing the next stage of Librela with Syngene, we continue to build a strong global supply network for Zoetis products and fulfill our purpose to nurture the world and humankind by advancing care for animals.”
